American medical technology giant Medtronic is set to establish operations in Serbia following a memorandum of understanding signed with Serbia’s Ministry of Science, Technological Development and Innovation.
This landmark agreement is expected to significantly boost Serbia’s scientific community by fostering advancements within the BIO4 campus, a strategic biotechnology hub in Southeast Europe.
The memorandum outlines collaborative efforts to strengthen Serbia’s bio-economic startup ecosystem and enhance scientific research, education, and innovation in biomedicine and biotechnology. Minister Jelena Begovic hailed the agreement as a significant achievement for Serbia’s scientific ecosystem, noting Medtronic’s reputation for developing cutting-edge medical devices since its founding in 1949.
Medtronic, employing nearly 100,000 people globally and investing almost $3 billion annually in R&D, views this partnership as a testament to Serbia’s growing status as an innovation hub. Majid Kadumi, Medtronic’s senior vice president for EMEA, praised Serbia’s impressive scientific heritage and potential for future benefits.
The collaboration promises to leverage Medtronic’s extensive expertise and Serbia’s innovative capabilities, marking a major step forward in the region’s biomedical and technological landscape.
Photo: Zoran Petrović/nitra.gov.rs